A comparison of pediatric, adolescent, and adult testicular germ cell malignancy

Nicholas G. Cost, Jessica D. Lubahn, Mehrad Adibi, Adam Romman, Jonathan E. Wickiser, Ganesh V. Raj, Arthur I. Sagalowsky, Vitaly Margulis

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Testicular germ cell tumors (T-GCTs) occur from infancy to adulthood, and are the most common solid tumor in adolescent and young adult males. Traditionally, pediatric T-GCTs were perceived as more indolent than adult T-GCTs. However, there are few studies comparing these groups and none that specifically evaluate adolescents. Methods: An institutional database of T-GCT patients was reviewed and patients were categorized into Pediatric, aged 0-12 years, Adolescent, aged 13-19 years, and Adult, older than 20 years, cohorts. Demographics, tumor characteristics, disease stage, treatment, event-free survival (EFS), and overall survival (OS) were compared between groups. Results: Overall, 413 patients (20 pediatric, 39 adolescent, 354 adult) met study criteria and were followed for a median of 2.0 years (0.1-23.6). Adolescents presented with more advanced stage than children (P=0.018) or adults (P=0.008). There was a higher rate of events in Adolescents (13, 33.3%) than in Adults (61, 17.2%) or Children (2, 10.0%). Three-year EFS was 87.2% in the Pediatric group, 59.9% in Adolescents and 80.0% in Adults (P=0.011). In a multivariate analysis, controlling for stage, IGCCCG risk, and histology, the hazard ratio (HR) for an event was: 1 (Reference) for Adults, HR=0.82 (95% CI 0.19-3.46; P=0.33) for the Pediatric group, and HR=2.22 (95% CI 1.21-4.07; P=0.01) for Adolescents. Five-year OS was 100% in the Pediatric group, 84.8% in Adolescents, and 92.8% in Adults (P=0.388). Conclusion: Lower EFS in adolescent T-GCT patients was observed than in either children or adults. Elucidating factors associated with inferior outcomes in adolescents is an important focus of future research.

Original languageEnglish (US)
Pages (from-to)446-451
Number of pages6
JournalPediatric Blood and Cancer
Volume61
Issue number3
DOIs
StatePublished - Mar 1 2014
Externally publishedYes

Fingerprint

Germ Cells
Pediatrics
Neoplasms
Disease-Free Survival
Survival
Young Adult
Histology
Multivariate Analysis
Demography
Testicular Germ Cell Tumor
Databases

Keywords

  • Adolescent oncology
  • Germ cell malignancy
  • Pediatric oncology
  • Testicular cancer

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Cost, N. G., Lubahn, J. D., Adibi, M., Romman, A., Wickiser, J. E., Raj, G. V., ... Margulis, V. (2014). A comparison of pediatric, adolescent, and adult testicular germ cell malignancy. Pediatric Blood and Cancer, 61(3), 446-451. https://doi.org/10.1002/pbc.24773

A comparison of pediatric, adolescent, and adult testicular germ cell malignancy. / Cost, Nicholas G.; Lubahn, Jessica D.; Adibi, Mehrad; Romman, Adam; Wickiser, Jonathan E.; Raj, Ganesh V.; Sagalowsky, Arthur I.; Margulis, Vitaly.

In: Pediatric Blood and Cancer, Vol. 61, No. 3, 01.03.2014, p. 446-451.

Research output: Contribution to journalArticle

Cost, NG, Lubahn, JD, Adibi, M, Romman, A, Wickiser, JE, Raj, GV, Sagalowsky, AI & Margulis, V 2014, 'A comparison of pediatric, adolescent, and adult testicular germ cell malignancy', Pediatric Blood and Cancer, vol. 61, no. 3, pp. 446-451. https://doi.org/10.1002/pbc.24773
Cost, Nicholas G. ; Lubahn, Jessica D. ; Adibi, Mehrad ; Romman, Adam ; Wickiser, Jonathan E. ; Raj, Ganesh V. ; Sagalowsky, Arthur I. ; Margulis, Vitaly. / A comparison of pediatric, adolescent, and adult testicular germ cell malignancy. In: Pediatric Blood and Cancer. 2014 ; Vol. 61, No. 3. pp. 446-451.
@article{c0b0710552e44abfb72d766ac9bd9805,
title = "A comparison of pediatric, adolescent, and adult testicular germ cell malignancy",
abstract = "Background: Testicular germ cell tumors (T-GCTs) occur from infancy to adulthood, and are the most common solid tumor in adolescent and young adult males. Traditionally, pediatric T-GCTs were perceived as more indolent than adult T-GCTs. However, there are few studies comparing these groups and none that specifically evaluate adolescents. Methods: An institutional database of T-GCT patients was reviewed and patients were categorized into Pediatric, aged 0-12 years, Adolescent, aged 13-19 years, and Adult, older than 20 years, cohorts. Demographics, tumor characteristics, disease stage, treatment, event-free survival (EFS), and overall survival (OS) were compared between groups. Results: Overall, 413 patients (20 pediatric, 39 adolescent, 354 adult) met study criteria and were followed for a median of 2.0 years (0.1-23.6). Adolescents presented with more advanced stage than children (P=0.018) or adults (P=0.008). There was a higher rate of events in Adolescents (13, 33.3{\%}) than in Adults (61, 17.2{\%}) or Children (2, 10.0{\%}). Three-year EFS was 87.2{\%} in the Pediatric group, 59.9{\%} in Adolescents and 80.0{\%} in Adults (P=0.011). In a multivariate analysis, controlling for stage, IGCCCG risk, and histology, the hazard ratio (HR) for an event was: 1 (Reference) for Adults, HR=0.82 (95{\%} CI 0.19-3.46; P=0.33) for the Pediatric group, and HR=2.22 (95{\%} CI 1.21-4.07; P=0.01) for Adolescents. Five-year OS was 100{\%} in the Pediatric group, 84.8{\%} in Adolescents, and 92.8{\%} in Adults (P=0.388). Conclusion: Lower EFS in adolescent T-GCT patients was observed than in either children or adults. Elucidating factors associated with inferior outcomes in adolescents is an important focus of future research.",
keywords = "Adolescent oncology, Germ cell malignancy, Pediatric oncology, Testicular cancer",
author = "Cost, {Nicholas G.} and Lubahn, {Jessica D.} and Mehrad Adibi and Adam Romman and Wickiser, {Jonathan E.} and Raj, {Ganesh V.} and Sagalowsky, {Arthur I.} and Vitaly Margulis",
year = "2014",
month = "3",
day = "1",
doi = "10.1002/pbc.24773",
language = "English (US)",
volume = "61",
pages = "446--451",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - A comparison of pediatric, adolescent, and adult testicular germ cell malignancy

AU - Cost, Nicholas G.

AU - Lubahn, Jessica D.

AU - Adibi, Mehrad

AU - Romman, Adam

AU - Wickiser, Jonathan E.

AU - Raj, Ganesh V.

AU - Sagalowsky, Arthur I.

AU - Margulis, Vitaly

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Background: Testicular germ cell tumors (T-GCTs) occur from infancy to adulthood, and are the most common solid tumor in adolescent and young adult males. Traditionally, pediatric T-GCTs were perceived as more indolent than adult T-GCTs. However, there are few studies comparing these groups and none that specifically evaluate adolescents. Methods: An institutional database of T-GCT patients was reviewed and patients were categorized into Pediatric, aged 0-12 years, Adolescent, aged 13-19 years, and Adult, older than 20 years, cohorts. Demographics, tumor characteristics, disease stage, treatment, event-free survival (EFS), and overall survival (OS) were compared between groups. Results: Overall, 413 patients (20 pediatric, 39 adolescent, 354 adult) met study criteria and were followed for a median of 2.0 years (0.1-23.6). Adolescents presented with more advanced stage than children (P=0.018) or adults (P=0.008). There was a higher rate of events in Adolescents (13, 33.3%) than in Adults (61, 17.2%) or Children (2, 10.0%). Three-year EFS was 87.2% in the Pediatric group, 59.9% in Adolescents and 80.0% in Adults (P=0.011). In a multivariate analysis, controlling for stage, IGCCCG risk, and histology, the hazard ratio (HR) for an event was: 1 (Reference) for Adults, HR=0.82 (95% CI 0.19-3.46; P=0.33) for the Pediatric group, and HR=2.22 (95% CI 1.21-4.07; P=0.01) for Adolescents. Five-year OS was 100% in the Pediatric group, 84.8% in Adolescents, and 92.8% in Adults (P=0.388). Conclusion: Lower EFS in adolescent T-GCT patients was observed than in either children or adults. Elucidating factors associated with inferior outcomes in adolescents is an important focus of future research.

AB - Background: Testicular germ cell tumors (T-GCTs) occur from infancy to adulthood, and are the most common solid tumor in adolescent and young adult males. Traditionally, pediatric T-GCTs were perceived as more indolent than adult T-GCTs. However, there are few studies comparing these groups and none that specifically evaluate adolescents. Methods: An institutional database of T-GCT patients was reviewed and patients were categorized into Pediatric, aged 0-12 years, Adolescent, aged 13-19 years, and Adult, older than 20 years, cohorts. Demographics, tumor characteristics, disease stage, treatment, event-free survival (EFS), and overall survival (OS) were compared between groups. Results: Overall, 413 patients (20 pediatric, 39 adolescent, 354 adult) met study criteria and were followed for a median of 2.0 years (0.1-23.6). Adolescents presented with more advanced stage than children (P=0.018) or adults (P=0.008). There was a higher rate of events in Adolescents (13, 33.3%) than in Adults (61, 17.2%) or Children (2, 10.0%). Three-year EFS was 87.2% in the Pediatric group, 59.9% in Adolescents and 80.0% in Adults (P=0.011). In a multivariate analysis, controlling for stage, IGCCCG risk, and histology, the hazard ratio (HR) for an event was: 1 (Reference) for Adults, HR=0.82 (95% CI 0.19-3.46; P=0.33) for the Pediatric group, and HR=2.22 (95% CI 1.21-4.07; P=0.01) for Adolescents. Five-year OS was 100% in the Pediatric group, 84.8% in Adolescents, and 92.8% in Adults (P=0.388). Conclusion: Lower EFS in adolescent T-GCT patients was observed than in either children or adults. Elucidating factors associated with inferior outcomes in adolescents is an important focus of future research.

KW - Adolescent oncology

KW - Germ cell malignancy

KW - Pediatric oncology

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=84892492734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892492734&partnerID=8YFLogxK

U2 - 10.1002/pbc.24773

DO - 10.1002/pbc.24773

M3 - Article

VL - 61

SP - 446

EP - 451

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -